170 related articles for article (PubMed ID: 38503729)
41. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.
Ma J; Liu B; Yu D; Zuo Y; Cai R; Yang J; Cheng J
Br J Haematol; 2019 Oct; 187(1):49-64. PubMed ID: 31236919
[TBL] [Abstract][Full Text] [Related]
42. Tingenone and 22-hydroxytingenone target oxidative stress through downregulation of thioredoxin, leading to DNA double-strand break and JNK/p38-mediated apoptosis in acute myeloid leukemia HL-60 cells.
Rodrigues ACBDC; Bomfim LM; Neves SP; Soares MBP; Dias RB; Valverde LF; Rocha CAG; Costa EV; da Silva FMA; Rocha WC; Koolen HHF; Bezerra DP
Biomed Pharmacother; 2021 Oct; 142():112034. PubMed ID: 34411914
[TBL] [Abstract][Full Text] [Related]
43. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Omsland M; Bruserud Ø; Gjertsen BT; Andresen V
Oncotarget; 2017 Jan; 8(5):7946-7963. PubMed ID: 27974700
[TBL] [Abstract][Full Text] [Related]
44. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.
Hassan HT
Leuk Res; 2004 Jul; 28(7):667-71. PubMed ID: 15158086
[TBL] [Abstract][Full Text] [Related]
45. Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway.
Jin Y; Yang Q; Liang L; Ding L; Liang Y; Zhang D; Wu B; Yang T; Liu H; Huang T; Shen H; Tu H; Pan Y; Wei Y; Yang Y; Zhou F
J Exp Clin Cancer Res; 2018 Nov; 37(1):277. PubMed ID: 30454068
[TBL] [Abstract][Full Text] [Related]
46. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.
Ahmed N; Laverick L; Sammons J; Zhang H; Maslin DJ; Hassan HT
Anticancer Res; 2001; 21(5):3519-23. PubMed ID: 11848518
[TBL] [Abstract][Full Text] [Related]
47. Bcl-2 protein in human myeloid leukaemia cells and its down-regulation during chemotherapy-induced apoptosis.
Ahmed N; Sammons J; Hassan HT
Oncol Rep; 1999; 6(2):403-7. PubMed ID: 10023011
[TBL] [Abstract][Full Text] [Related]
48. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
49. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation.
Liu JM; Pan F; Li L; Liu QR; Chen Y; Xiong XX; Cheng K; Yu SB; Shi Z; Yu AC; Chen XQ
Biochem Biophys Res Commun; 2013 Jul; 437(1):87-93. PubMed ID: 23796709
[TBL] [Abstract][Full Text] [Related]
50. Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-κB inhibition in acute myeloid leukemia cells.
Zhang H; Xu H; Zhang R; Zhao X; Liang M; Wei F
Cancer Chemother Pharmacol; 2020 Aug; 86(2):257-266. PubMed ID: 32696214
[TBL] [Abstract][Full Text] [Related]
51. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
[TBL] [Abstract][Full Text] [Related]
52. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.
Guzman ML; Neering SJ; Upchurch D; Grimes B; Howard DS; Rizzieri DA; Luger SM; Jordan CT
Blood; 2001 Oct; 98(8):2301-7. PubMed ID: 11588023
[TBL] [Abstract][Full Text] [Related]
53. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Grosjean-Raillard J; Tailler M; Adès L; Perfettini JL; Fabre C; Braun T; De Botton S; Fenaux P; Kroemer G
Oncogene; 2009 Feb; 28(8):1099-109. PubMed ID: 19079347
[TBL] [Abstract][Full Text] [Related]
54. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways.
Grandage VL; Gale RE; Linch DC; Khwaja A
Leukemia; 2005 Apr; 19(4):586-94. PubMed ID: 15703783
[TBL] [Abstract][Full Text] [Related]
55. Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells.
Olme CH; Brown N; Finnon R; Bouffler SD; Badie C
Mutat Res; 2013 Aug; 756(1-2):119-26. PubMed ID: 23665297
[TBL] [Abstract][Full Text] [Related]
56. Strongylocentrotus nudos Egg Polysaccharide induces autophagy and apoptosis in leukaemia cells by regulating mitochondrial function.
Wang C; Li M; Li L; Shen X; Liu Y; Wang S
J Cell Mol Med; 2021 Jan; 25(1):272-283. PubMed ID: 33289295
[TBL] [Abstract][Full Text] [Related]
57. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
Lindhagen E; Eriksson A; Wickström M; Danielsson K; Grundmark B; Henriksson R; Nygren P; Aleskog A; Larsson R; Höglund M
Eur J Haematol; 2008 Nov; 81(5):344-53. PubMed ID: 18637032
[TBL] [Abstract][Full Text] [Related]
58. BH3 mimetic ABT-737 induces apoptosis in CD34
Rao J; Li F; Zhang RY; Zhou HH; Chen GA
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e144-e152. PubMed ID: 26552712
[TBL] [Abstract][Full Text] [Related]
59. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
[TBL] [Abstract][Full Text] [Related]
60. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
